Advertisement Eli Lilly, T1D Exchange enter research collaboration for new type 1 diabetes treatments - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Eli Lilly, T1D Exchange enter research collaboration for new type 1 diabetes treatments

Eli Lilly and Company has entered into a research collaboration with T1D Exchange to discover new ways to improve care and advance outcomes for patients with type 1 diabetes (T1D).

The partnership, which will include multiple projects over an initial five-year period, will allow the companies to gain deeper, real-world insight about the experience of these patients.

As part of the collaboration, the two firms will engage in a range of projects that combine Lilly’s expertise in type 1 diabetes with T1D Exchange’s new patient-centric model that connects a clinic registry of over 26,000 people with T1D and Glu, a patient and caregiver online community for T1D.

Lilly Diabetes medical fellow Dara Schuster said, "Having access to the resources of T1D Exchange to bolster our understanding of the needs of people with type 1 diabetes, their caregivers and health care providers will help us continue our mission of addressing the global diabetes burden through the development of innovative medicines and programs."

The companies’ first project will assess how children and adults with T1D manage the disease over time with insulin pumps and multiple daily injections.

Initially, T1D Exchange data will be analyzed to inform development of a survey of health care providers from the clinic network and members of the Glu community.

After the survey, a new trial of clinic registry participants is planned, to further analyze how insulin pumps are used and how multiple daily injections occur in real-world practice.

After completion of the analysis, data and recommendations from the research will be shared publicly to benefit both T1D and researcher communities.